FAQ/Help |
Calendar |
Search |
Today's Posts |
04-03-2012, 03:19 PM | #1 | ||
|
|||
In Remembrance
|
from pipeline email:
Mar 30, 2012 Amsterdam Molecular Therapeutics Announces Results of Extraordinary General Meeting Amsterdam, The Netherlands – March 30, 2012 – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that the Extraordinary General Meeting (EGM) of shareholders was held in Amsterdam, the Netherlands, today in accordance with the EGM Notice of February 17, 2012. At the EGM, shareholders approved all the resolutions proposed for the substantial corporate restructuring and financing transaction, which will result in the assets and certain liabilities being acquired by a newly formed private company, uniQure BV, and the AMT legal entity being liquidated. The shareholders in uniQure previously included a condition to the transaction that meant an additional € 1.0 million of investment was to be secured by AMT prior to completion. This condition has been waived. Completion of the uniQure transaction is expected to occur in early April 2012. Further details on timing on the uniQure transaction are set out on the company’s website. The resolutions put to the EGM convened in accordance with the Notice were passed by a majority in excess of 99 percent. The detailed voting information and results pursuant to Section 2:120 paragraph 5 of the Dutch Civil Code will be posted on the website www.amtbiopharma.com. About Amsterdam Molecular Therapeutics AMT is a world leader in the development of human gene based therapies. AMT has a product pipeline of gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson’s disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world’s first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry. The assets of AMT are subject to a proposed acquisition by uniQure BV. AMT was founded in 1998 and is based in Amsterdam. Further information can be found at www.amtbiopharma.com. About uniQure uniQure BV is a private company created specifically to acquire specific assets and liabilities of Amsterdam Molecular Therapeutics (AMT). The company is funded by Forbion Capital Partners, an existing investor in AMT. uniQure will act as the new holding company for the gene therapy business currently carried out by AMT. For further enquiries: Jörn Aldag CEO AMT Tel : +31 20 566 7394 j.aldag@amtbiopharma.com Mike Sinclair Partner Halsin Partners Tel : +44 20 7318 2955 msinclair@halsin.com
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
Reply With Quote |
|
|
Similar Threads | ||||
Thread | Forum | |||
Aav2-gdnf | Parkinson's Disease | |||
gdnf...it's back? | Parkinson's Disease | |||
Gdnf | Parkinson's Disease | |||
The GDNF fiasco | Parkinson's Disease | |||
GDNF Book | Parkinson's Disease |